Remove 2004 Remove Leads Remove Patients
article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. But it’s still the leading cause of cancer deaths. Although lung cancer’s mortality rate has fallen, the disease is still the leading cause of cancer deaths.

Medicine 271
article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

However, patient uptake hasn’t matched rising market competition. And among patients who have tried preventive medications for migraine, 39% said they no longer took them. These low adoption rates highlight the need for more migraine-drug awareness and suggest that pharma marketers should explore new strategies to boost patient uptake.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.

Patients 104
article thumbnail

European Commission revokes marketing authorisation for Novartis’ crizanlizumab

European Pharmaceutical Review

Crizanlizumab is a once-a-month, humanised monoclonal antibody infusion, indicated for the prevention of recurrent vaso‑occlusive crises (pain crises) in sickle cell disease patients aged 16 years and above. Adakveo (crizanlizumab) received conditional authorisation by the EC in October 2020.

article thumbnail

Teva appoints Eric Hughes as head of R&D and Chief Medical Officer

European Pharmaceutical Review

At the beginning of his career in 2004, Dr Hughes was responsible for early clinical research at Bristol Myers-Squibb Company and then at Schering-Plough Research Institute. ” Since September 2021, Dr Hughes has been Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals, based in Boston. .”

Medical 98
article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. These changes are summarised in Table 1.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. Reducing market exclusivity. Conclusions.